SCHEMBL19511684

SCHEMBL19511684

COc1ccc2c(Oc3ccc(NC(=O)c4cc(C(F)(F)F)cn(-c5ccccc5)c4=O)nc3)ccnc2c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2B Q14289 6/20 0.75
PTK2 Q05397 1/20 0.66
IGF1R P08069 14/20 0.63
MET P08581 14/20 0.63
KDR P35968 13/20 0.63
AURKA O14965 1/20 0.60
JAK2 O60674 1/20 0.60
RPS6KA5 O75582 1/20 0.60
ABL1 P00519 1/20 0.60
INSR P06213 1/20 0.60
LCK P06239 1/20 0.60
FES P07332 1/20 0.60
CSF1R P07333 1/20 0.60
LYN P07948 1/20 0.60
RET P07949 1/20 0.60
FGR P09769 1/20 0.60
KIT P10721 1/20 0.60
PIM1 P11309 1/20 0.60
FGFR1 P11362 1/20 0.60
SRC P12931 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19511666 0.94 PTK2B (0.67) PTK2BPTK2IGF1RMETKDR
SCHEMBL19511988 0.92 PTK2B (0.77) PTK2BPTK2IGF1RMETKDR
SCHEMBL198261 0.86 PTK2B (1.00) PTK2BPTK2IGF1RMETKDR
SCHEMBL19512004 0.86 PTK2B (0.70) PTK2BPTK2IGF1RMETKDR
SCHEMBL200771 0.85 PTK2B (1.00) PTK2BPTK2IGF1RMETKDR
SCHEMBL198583 0.83 IGF1R (0.75) PTK2BIGF1RMETKDRAURKA
SCHEMBL19511441 0.81 PTK2B (0.80) PTK2BPTK2IGF1RMETKDR
SCHEMBL19511748 0.81 PTK2B (0.78) PTK2BPTK2IGF1RMETKDR
SCHEMBL13467667 0.81 PTK2B (0.65) PTK2BPTK2IGF1RMETKDR
SCHEMBL12120994 0.80 IGF1R (0.74) PTK2BPTK2IGF1RMETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3239147-B1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2019-08-28 EP claimed
EP-3239147-B1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2019-08-28 EP disclosed
US-10208034-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-19 US disclosed
US-20170349583-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-12-07 US disclosed
EP-3239147-A1 QUINOLINE DERIVATIVE Ono Pharmaceutical Co., Ltd. (JP) 2017-11-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349583-A1 QUINOLINE DERIVATIVE FLT3, AXL, ABL1 PTK2B 52/4885PTK2 284/4885IGF1R 122/4885
US-10208034-B2 Quinoline derivative FLT3, AXL, ABL1 PTK2B 52/4885PTK2 284/4885IGF1R 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.